TORONTO, ONTARIO–(Marketwired – Sept. 12, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF), announced today it has increased the size of the non-brokered private placement the Company previously announced in a press release August 10, 2017, from $155,000 to $200,000 (the “Offering”).
Press Releases
Arch Biopartners Provides Update on GMP Manufacturing of AB569
TORONTO, ONTARIO–(Marketwired – July 27, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) today provided an update on the progress of the good manufacturing practice (GMP) production campaign for AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients.
Arch Biopartners Retains Market Maker and Arranges Non Brokered Private Placement Financing
TORONTO, ONTARIO–(Marketwired – July 24, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announced today it has retained Mackie Research Capital Corporation (“Mackie Research”) to provide market-making services to the Company in compliance with, and subject to, the policies, guidelines and approval of the TSX Venture Exchange and other applicable legislation.
Arch Biopartners Announces Start of GMP Manufacturing for AB569 at Dalton Pharma Services
TORONTO, ONTARIO–(Marketwired – May 4, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced Dalton Pharma Services (Dalton) has launched the good manufacturing practice (GMP) campaign for AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.
Grant of Options to Directors, Officers and Scientists
TORONTO, ONTARIO–(Marketwired – April 18, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announces the Company’s board has granted a total of 2,100,000 stock options to its directors, officers and certain scientists pursuant to the Company’s stock option plan and the requirements of the TSX Venture Exchange (TSXV).
Arch Biopartners’ Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial
TORONTO, ONTARIO–(Marketwired – April 13, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced that the Cincinnati Veterans Affairs Medical Center (CVAMC) will conduct an investigator initiated Phase I human trial to evaluate the safety and pharmacokinetic profile of AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.
Arch Biopartners Closes Non-Brokered Private Placement Financing
TORONTO, ONTARIO–(Marketwired – Feb. 28, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:FOIFF) a portfolio based biotechnology company, announced today it has raised $400,000 with the closing of the non-brokered private placement the Company announced in a press release February 21, 2017 (The “Offering”).
Arch Biopartners Announces TSXV Stock Ticker Symbol Change to “ARCH”
TORONTO, ONTARIO–(Marketwired – Feb. 23, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, announced today that the Company’s common shares will begin trading under the new stock ticker symbol “ARCH” on the TSX Venture Exchange (TSXV), effective at the open of trading on February 24, 2017.
Arch Biopartners Announces Non-Brokered Private Placement Financing
TORONTO, ONTARIO–(Marketwired – Feb. 21, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 1,000,000 common shares priced at $0.40 per common share (the “Common Shares”) for gross proceeds of up to $400,000 (the “Offering”).
Arch Biopartners Appoints Patrick Vink to Board of Directors
TORONTO, CANADA–(Marketwired – Dec. 12, 2016) – Arch Biopartners, Inc., (TSX VENTURE:ACH) (OTCBB:FOIFF) (Arch or the Company) is pleased to announce that Dr. Patrick Vink has joined its Board of Directors effective December 12th, 2016.